文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症疾病对侵袭性血液恶性肿瘤患者抗肿瘤治疗延续及预后的影响

Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies.
PubMed 文献 · Ann Intensive Care · 2024-09-11
一句话结论ICU存活出院的AML或侵袭性B-NHL患者中58%能恢复原定抗肿瘤方案,年龄>65岁、出ICU时高胆红素血症及治疗限制决策独立预测方案修改,方案修改与1年预后恶化相关。

该单中心回顾性观察研究纳入2013-2021年ICU非计划入住后存活出院的AML(n=92)和B-NHL(n=78)患者共170例,评估ICU出院后抗肿瘤治疗方案的改变及1年无进展生存和总生存。结果显示42%患者需修改血液肿瘤治疗方案,58%能恢复原定方案;年龄>65岁(OR 3.54)、ICU出院时高胆红素血症>20 µmol/L(OR 3.01)和治疗限制决策(OR 16.5)是方案修改的独立决定因素。ICU出院后1年生存率为59.5%,方案修改与院内、1年总生存和无进展生存显著相关。

要点

  • 170例ICU存活出院的AML或B-NHL患者中,42%(72例)需修改原定血液肿瘤治疗方案,58%能恢复原定方案。
  • 年龄>65岁(OR 3.54,95%CI 1.67-7.50,p<0.001)是ICU出院后修改抗肿瘤方案的独立决定因素。
  • ICU出院时高胆红素血症>20 µmol/L(OR 3.01,95%CI 1.10-8.15,p=0.031)独立关联方案修改。
  • 治疗限制决策(OR 16.5,95%CI 1.83-149.7,p=0.012)与方案修改独立相关。
  • ICU出院后1年生存率59.5%,方案修改与院内、1年总生存及无进展生存显著相关。

适用人群与场景

  • 2013-2021年单中心ICU非计划入住后存活出院的成人AML或侵袭性B-NHL患者(n=170,AML 92例、B-NHL 78例)。
  • 68%患者血液恶性肿瘤为近期诊断;入ICU时SOFA评分中位数5(四分位距4-8)。

研究设计与关键结果

  • 研究类型:2013-2021年单中心回顾性观察研究;纳入ICU非计划入住后存活出院的AML或B-NHL患者170例(AML n=92,B-NHL n=78)。
  • ICU期间30例(17.6%)需有创机械通气,29例(17.0%)需血管活性药物支持,16例(9.4%)需肾脏替代治疗。
  • 主要终点:ICU出院后需修改血液肿瘤治疗方案者72例(42%),即58%能恢复原定方案。
  • 多因素分析:年龄>65岁(OR 3.54,95%CI 1.67-7.50,p<0.001)、ICU出院时高胆红素血症>20 µmol/L(OR 3.01,95%CI 1.10-8.15,p=0.031)、治疗限制决策(OR 16.5,95%CI 1.83-149.7,p=0.012)独立关联治疗方案修改。
  • ICU出院后1年生存率59.5%;ICU出院后治疗方案修改对院内生存、1年总生存和无进展生存有显著影响。

证据类型、等级与局限

  • 证据类型:单中心回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对ICU存活出院的侵袭性血液恶性肿瘤患者,出ICU时应评估年龄、胆红素及治疗限制决策,以识别抗肿瘤方案可能需要修改的高危患者。
  • 原文结论提示ICU出院后治疗方案修改与1年预后恶化相关,但未据此给出具体推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Maintaining the dose-intensity of cancer treatment is an important prognostic factor of aggressive hematological malignancies. The objective of this study was to assess the long-term outcomes of intensive care unit (ICU) survivors with acute myeloid leukemia (AML) or aggressive B-cell non-Hodgkin lymphoma (B-NHL) with emphasis on the resumption of the intended optimal regimen of cancer treatment.

PATIENTS AND METHODS: We conducted a retrospective (2013-2021) single-center observational study where we included patients with AML and B-NHL discharged alive from the ICU after an unplanned admission. The primary endpoint was the change in the intended optimal cancer treatment following ICU discharge. Secondary endpoints were 1-year progression-free survival and overall survival rates. Determinants associated with modifications in cancer treatment were assessed through multivariate logistic regression.

RESULTS: Over the study period, 366 patients with AML or B-NHL were admitted to the ICU, of whom 170 survivors with AML (n = 92) and B-NHL (n = 78) formed the cohort of interest. The hematological malignancy was recently diagnosed in 68% of patients. The admission Sequential Organ Failure Assessment (SOFA) score was 5 (interquartile range 4-8). During the ICU stay, 30 patients (17.6%) required invasive mechanical ventilation, 29 (17.0%) vasopressor support, and 16 (9.4%) renal replacement therapy. The one-year survival rate following ICU discharge was 59.5%. Further modifications in hematologic treatment regimens were required in 72 patients (42%). In multivariate analysis, age > 65 years (odds ratio (OR) 3.54 [95%-confidence interval 1.67-7.50], p < 0.001), ICU-discharge hyperbilirubinemia > 20 µmol/L (OR 3.01 [1.10-8.15], p = 0.031), and therapeutic limitations (OR 16.5 [1.83-149.7], p = 0.012) were independently associated with modifications in cancer treatment. Post-ICU modifications of cancer treatment had significant impact on in-hospital, 1-year overall survival and progression-free survival.

CONCLUSION: The intended cancer treatment could be resumed in 58% of ICU survivors with aggressive hematological malignancies. At the time of ICU discharge, advanced age, persistent liver dysfunction and decisions to limit further life-support therapies were independent determinants of cancer treatment modifications. These modifications were associated with worsened one-year outcomes.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Bredin S, Decroocq J, Devautour C, et al. Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies. Ann Intensive Care. 2024. PMID: 39259434. doi:10.1186/s13613-024-01372-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。